Drug intelligence / Profile preview

MR19D6A

Development stage: Unknown
Lead developer: Maruishi Pharmaceutical
Modality: Small Molecules
Administration: Topical

Overview

MR19D6A is an investigational topical formulation of metronidazole developed by Maruishi Pharmaceutical for the management of malodorous cancerous cutaneous ulcers. Metronidazole is a nitroimidazole antibiotic that is effective against anaerobic bacteria, which are the primary cause of the offensive odor associated with necrotic tumor tissues in advanced cancer. MR19D6A is designed to provide localized antibacterial activity with minimal systemic absorption. In clinical studies, it has been evaluated for safety, pharmacokinetics, and usability in comparison to Rozex Gel (0.75% metronidazole), the standard topical treatment for this indication in Japan.

Other names: metronidazole

Targets

DNA

Beyond the preview

Go deeper on MR19D6A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MR19D6A.

Explore the full profile